Company / EPS (Diluted)
Pacira BioSciences, Inc. EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
$0.89
FY2025
5-year range
-$2.15 / $3.33
FY2021-FY2025
Trend
+141.4%
vs FY2024
Sector context
#31 of 204
Health Care
What the data says
Pacira BioSciences, Inc.'s eps (diluted) of $0.89 is higher than 85% of companies in the Health Care sector (FY2025). EPS (Diluted) returned to growth in FY2025 after 2 years of decline, reaching $0.89.
Based on SEC 10-K filings.
0.89 in FY2025 with a 3-year CAGR of -35.6%. Top quartile in the Health Care sector.
Declined from $0.92 to $0.89 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -35.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 15% in Health CareTop 15% of 204This company $0.89 Sector average -$0.98
▼
+190.9% above sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 141.4% year-over-year.
- Ranks #31 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2022.
- Lowest eps (diluted) in the period was in FY2024.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Negative profit margin: -14.8%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.89 | +141.4% |
| FY2024 | -$2.15 | -333.7% |
| FY2023 | $0.92 | -72.4% |
| FY2022 | $3.33 | +1333.3% |
| FY2021 | -$0.27 | -2600.0% |
| FY2020 | -$0.01 | +85.7% |
| FY2019 | -$0.07 | +93.1% |
| FY2018 | -$1.02 | -2650.0% |
| FY2017 | $0.04 | +0.0% |
| FY2016 | $0.04 | +102.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026